EG25699A - N-aryl piperidine substituted biphenylcarboxamides - Google Patents

N-aryl piperidine substituted biphenylcarboxamides

Info

Publication number
EG25699A
EG25699A EG2003080749A EG2003080749A EG25699A EG 25699 A EG25699 A EG 25699A EG 2003080749 A EG2003080749 A EG 2003080749A EG 2003080749 A EG2003080749 A EG 2003080749A EG 25699 A EG25699 A EG 25699A
Authority
EG
Egypt
Prior art keywords
piperidine substituted
aryl piperidine
biphenylcarboxamides
substituted biphenylcarboxamides
aryl
Prior art date
Application number
EG2003080749A
Other languages
English (en)
Inventor
Lieven Meerpoel
Leo Jacobus Jozef Backx
Peter Walter Maria Roevens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of EG25699A publication Critical patent/EG25699A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EG2003080749A 2002-08-12 2003-08-02 N-aryl piperidine substituted biphenylcarboxamides EG25699A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12

Publications (1)

Publication Number Publication Date
EG25699A true EG25699A (en) 2012-05-22

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2003080749A EG25699A (en) 2002-08-12 2003-08-02 N-aryl piperidine substituted biphenylcarboxamides

Country Status (32)

Country Link
US (2) US20060040989A1 (zh)
EP (1) EP1536796B1 (zh)
JP (1) JP4559856B2 (zh)
KR (1) KR101052204B1 (zh)
CN (3) CN101165053A (zh)
AR (1) AR040968A1 (zh)
AT (1) ATE385796T1 (zh)
AU (1) AU2003250215B2 (zh)
BR (1) BR0313377A (zh)
CA (1) CA2494208C (zh)
CY (1) CY1107945T1 (zh)
DE (1) DE60319097T2 (zh)
DK (1) DK1536796T3 (zh)
EA (1) EA008061B1 (zh)
EG (1) EG25699A (zh)
ES (1) ES2301873T3 (zh)
HK (1) HK1083451A1 (zh)
HR (1) HRP20050103B1 (zh)
IL (1) IL166795A (zh)
IS (1) IS2726B (zh)
MX (1) MXPA05001712A (zh)
MY (1) MY136632A (zh)
NO (1) NO329308B1 (zh)
NZ (1) NZ538680A (zh)
PA (1) PA8579901A1 (zh)
PL (1) PL212405B1 (zh)
PT (1) PT1536796E (zh)
SI (1) SI1536796T1 (zh)
TW (1) TWI342775B (zh)
UA (1) UA79300C2 (zh)
WO (1) WO2004017969A1 (zh)
ZA (1) ZA200501225B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US20100004320A1 (en) 2006-04-03 2010-01-07 Santaris Pharma A/S Pharmaceutical Composition
EA201100811A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2008113832A2 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
JP2010521193A (ja) * 2007-03-22 2010-06-24 サンタリス ファーマ アー/エス Apo−b100発現の阻害のためのrnaアンタゴニスト化合物
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
US8440637B2 (en) 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
EP2421970B1 (en) * 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
LT3013959T (lt) 2013-06-27 2020-03-10 Roche Innovation Center Copenhagen A/S Priešprasmiai oligomerai ir konjugatai, nukreirti į pcsk9
US9790237B2 (en) 2014-06-16 2017-10-17 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
DE69332792T2 (de) 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
PL336481A1 (en) * 1997-04-18 2000-06-19 Pfizer Method of obtaining (1,2,3,4- tetrahydroisoquinolin -6-yl) amide of 4'-trifluoromethylbiphenyl-2-carboxylic acid and intermediate compounds
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
WO2003002582A1 (en) * 2001-06-27 2003-01-09 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CN1674900A (zh) 2005-09-28
PT1536796E (pt) 2008-05-13
TW200412954A (en) 2004-08-01
CA2494208A1 (en) 2004-03-04
EP1536796A1 (en) 2005-06-08
HK1083451A1 (en) 2006-07-07
DE60319097D1 (de) 2008-03-27
AU2003250215A1 (en) 2004-03-11
JP4559856B2 (ja) 2010-10-13
ATE385796T1 (de) 2008-03-15
NZ538680A (en) 2006-01-27
AU2003250215B2 (en) 2009-01-22
NO329308B1 (no) 2010-09-27
MXPA05001712A (es) 2005-04-19
TWI342775B (en) 2011-06-01
CN101165052B (zh) 2012-04-18
HRP20050103B1 (hr) 2013-09-30
PA8579901A1 (es) 2005-03-03
DE60319097T2 (de) 2009-06-04
PL212405B1 (pl) 2012-09-28
CN101165053A (zh) 2008-04-23
DK1536796T3 (da) 2008-06-09
EA200500348A1 (ru) 2005-08-25
ES2301873T3 (es) 2008-07-01
CA2494208C (en) 2011-05-10
KR20050026483A (ko) 2005-03-15
NO20050563L (no) 2005-01-31
US20060040989A1 (en) 2006-02-23
CN100366252C (zh) 2008-02-06
ZA200501225B (en) 2006-07-26
AR040968A1 (es) 2005-04-27
MY136632A (en) 2008-11-28
SI1536796T1 (sl) 2008-08-31
HRP20050103A2 (en) 2006-09-30
UA79300C2 (en) 2007-06-11
PL373379A1 (en) 2005-08-22
WO2004017969A1 (en) 2004-03-04
EA008061B1 (ru) 2007-02-27
US20090156623A1 (en) 2009-06-18
JP2006500371A (ja) 2006-01-05
IS2726B (is) 2011-03-15
US8258304B2 (en) 2012-09-04
IL166795A0 (en) 2006-01-15
EP1536796B1 (en) 2008-02-13
BR0313377A (pt) 2005-07-12
CN101165052A (zh) 2008-04-23
IL166795A (en) 2010-11-30
CY1107945T1 (el) 2013-09-04
IS7622A (is) 2004-12-29
KR101052204B1 (ko) 2011-07-29

Similar Documents

Publication Publication Date Title
HK1072251A1 (en) Piperidine derivative
HUS1400037I1 (hu) Új 2-piridiletilbenzamid származékok
EP1549646A4 (en) DERIVATIVES OF PIPERIDINE
ZA200500294B (en) Novel 2-pyridylethylbenzamide derivative
IL163652A0 (en) Substituted hydroxyethylamines
HK1077066A1 (en) Novel piperidine compound
EG25699A (en) N-aryl piperidine substituted biphenylcarboxamides
GB0307666D0 (en) Swing
IL166740A0 (en) Substituted heterocyclylpyrimidines
SI1487778T1 (sl) Substituirani 4-aminocikloheksanoli
GB2387414B (en) Hinges
GB0208928D0 (en) Methods
GB0220045D0 (en) Methods
GB0221711D0 (en) Methods
PL377325A1 (pl) Podstawione benzodioksepiny
GB0204967D0 (en) Methods
GB0219723D0 (en) Methods
GB0211384D0 (en) Viscometers
GB0222276D0 (en) Methods
GB0213580D0 (en) Methods
GB0200526D0 (en) Methods
SI1472256T1 (sl) Piperidinovi derivati
HK1081943A1 (en) N-hydroxyformamidine derivative
IL152801A0 (en) Swing
TW534178U (en) Improved hinges